{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:04:23Z","timestamp":1791475463748,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bone.2020.115664","type":"journal-article","created":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:50:39Z","timestamp":1601081439000},"page":"115664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia"],"prefix":"10.1016","volume":"142","author":[{"given":"Lothar","family":"Seefried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Denker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Watsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Dahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.bone.2020.115664_bb0005","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1073\/pnas.85.20.7666","article-title":"A missense mutation in the human liver\/bone\/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia","volume":"85","author":"Weiss","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2020.115664_bb0010","doi-asserted-by":"crossref","unstructured":"M.P. Whyte, J.D. Mahuren, L.A. Vrabel, S.P. Coburn, Markedly increased circulating pyridoxal-5\u2032-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism, J. Clin. Invest. 76(2) (1985) 752\u2013756, doi: https:\/\/doi.org\/10.1172\/jci112031.","DOI":"10.1172\/JCI112031"},{"issue":"5065","key":"10.1016\/j.bone.2020.115664_bb0015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"issue":"7410","key":"10.1016\/j.bone.2020.115664_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(65)91422-4","article-title":"Excretion of inorganic pyrophosphate in hypophosphatasia","volume":"2","author":"Russell","year":"1965","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2020.115664_bb0025","first-page":"380","article-title":"Hypophosphatasia","volume":"10","author":"Rockman-Greenberg","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bone.2020.115664_bb0030","doi-asserted-by":"crossref","unstructured":"S. Baumgartner-Sigl, E. Haberlandt, S. Mumm, S. Scholl-Burgi, C. Sergi, L. Ryan, K.L. Ericson, M.P. Whyte, W. Hogler, Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene, Bone 40(6) (2007) 1655-1661, doi: https:\/\/doi.org\/10.1016\/j.bone.2007.01.020.","DOI":"10.1016\/j.bone.2007.01.020"},{"issue":"2","key":"10.1016\/j.bone.2020.115664_bb0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00198-018-4691-6","article-title":"Neurological symptoms in hypophosphatasia","volume":"30","author":"Colazo","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2020.115664_bb0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.bone.2020.115664_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-016-0309-0","article-title":"Hypophosphatasia","volume":"14","author":"Linglart","year":"2016","journal-title":"Curr Osteoporos Rep."},{"issue":"1","key":"10.1016\/j.bone.2020.115664_bb0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","article-title":"Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry","volume":"20","author":"H\u00f6gler","year":"2019","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"10.1016\/j.bone.2020.115664_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bone.2013.01.024","article-title":"Clinical spectrum of hypophosphatasia diagnosed in adults","volume":"54","author":"Berkseth","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115664_bb0060","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","article-title":"Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys","volume":"65","author":"Weber","year":"2016","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.bone.2020.115664_bb0065","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00198-011-1528-y","article-title":"Skeletal mineralization defects in adult hypophosphatasia\u2014a clinical and histological analysis","volume":"22","author":"Barvencik","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115664_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bonr.2016.08.004","article-title":"Case series: odontohypophosphatasia or missed diagnosis of childhood\/adult-onset hypophosphatasia? - call for a long-term follow-up of premature loss of primary teeth","volume":"5","author":"Mori","year":"2016","journal-title":"Bone. Rep."},{"key":"10.1016\/j.bone.2020.115664_bb0075","unstructured":"Strensiq [package insert], Alexion Pharmaceuticals, Inc., Boston, MA, 2018."},{"key":"10.1016\/j.bone.2020.115664_bb0080","doi-asserted-by":"crossref","unstructured":"M.P. Whyte, C.R. Greenberg, N.J. Salman, M.B. Bober, W.H. McAlister, D. Wenkert, B.J. Van Sickle, J.H. Simmons, T.S. Edgar, M.L. Bauer, M.A. Hamdan, N. Bishop, R.E. Lutz, M. McGinn, S. Craig, J.N. Moore, J.W. Taylor, R.H. Cleveland, W.R. Cranley, R. Lim, T.D. Thacher, J.E. Mayhew, M. Downs, J.L. Millan, A.M. Skrinar, P. Crine, H. Landy, Enzyme-replacement therapy in life-threatening hypophosphatasia [with Supplementary Appendix], N. Engl. J. Med. 1366(10) (2012) 904\u2013913, doi: https:\/\/doi.org\/10.1056\/NEJMoa1106173.","DOI":"10.1056\/NEJMoa1106173"},{"issue":"1","key":"10.1016\/j.bone.2020.115664_bb0085","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2020.115664_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial [with Supplementary Appendix]","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.bone.2020.115664_bb0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia [with On-line Only Supplement]","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.bone.2020.115664_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115664_bb0105","unstructured":"Strensiq [summary of product characteristics], Alexion Europe, Rueil-Malmaison, France, 2018."},{"key":"10.1016\/j.bone.2020.115664_bb0110","unstructured":"Strensiq [prescribing information], Alexion Pharma GK, Tokyo, Japan, 2017."},{"issue":"7","key":"10.1016\/j.bone.2020.115664_bb0115","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI107336","article-title":"Identification of inorganic pyrophosphate in human platelets and its release on stimulation with thrombin","volume":"52","author":"Silcox","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2020.115664_bb0120","doi-asserted-by":"crossref","unstructured":"P.S.M. Caines, R.J. Thibert, T.F. Draisey, An improved fluorometric coupled enzymatic method for the determination of pyrophosphate in plasma and platelets, Microchem. J. 29(2) (1984) 168\u2013181, doi: https:\/\/doi.org\/10.1016\/0026-265X(84)90062-6.","DOI":"10.1016\/0026-265X(84)90062-6"},{"issue":"2","key":"10.1016\/j.bone.2020.115664_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MBC.0b013e32835a0824","article-title":"Microparticle counts in platelet-rich and platelet-free plasma, effect of centrifugation and sample-processing protocols","volume":"24","author":"Chandler","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bone.2020.115664_bb0130","unstructured":"Univesity of Versailles-San Quentin, The Tissue Nonspecific Alkaline Phosphatase Gene Mutations Database [Mornet E, editor]. http:\/\/www.sesep.uvsq.fr\/03_hypo_mutations.php, 2020 (accessed April 9, 2020)."},{"issue":"5","key":"10.1016\/j.bone.2020.115664_bb0135","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jbmr.2420","article-title":"Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification","volume":"30","author":"Sheen","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115664_bb0140","doi-asserted-by":"crossref","unstructured":"A.Y. Savinov, M. Salehi, M.C. Yadav, I. Radichev, J.L. Millan, O.V. Savinova, Transgenic overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in vascular endothelium results in generalized arterial calcification, J. Am. Heart Assoc. 4(12) (2015) doi: https:\/\/doi.org\/10.1161\/jaha.115.002499.","DOI":"10.1161\/JAHA.115.002499"},{"key":"10.1016\/j.bone.2020.115664_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2019.02.025","article-title":"No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia","volume":"122","author":"Whyte","year":"2019","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2020.115664_bb0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13244-016-0534-1","article-title":"Error and discrepancy in radiology: inevitable or avoidable?","volume":"8","author":"Brady","year":"2017","journal-title":"Insights Imaging."},{"issue":"7","key":"10.1016\/j.bone.2020.115664_bb0155","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/ICO.0000000000001947","article-title":"Ectopic ocular surface calcification in patients with hypophosphatasia treated with asfotase alfa","volume":"38","author":"Gospe","year":"2019","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.bone.2020.115664_bb0160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1101\/gad.1276205","article-title":"Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone","volume":"19","author":"Murshed","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.bone.2020.115664_bb0165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fcvm.2018.00196","article-title":"Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet","volume":"5","author":"Back","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.bone.2020.115664_bb0170","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/ATVBAHA.114.304017","article-title":"ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report","volume":"34","author":"Jansen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1\u20132","key":"10.1016\/j.bone.2020.115664_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","article-title":"Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa","volume":"122","author":"Kishnani","year":"2017","journal-title":"Mol. Genet. Metab."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220304440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220304440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:53:14Z","timestamp":1757613194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220304440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":35,"alternative-id":["S8756328220304440"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115664","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115664"}}